Lakewood-Amedex has a strong and well developed intellectual property portfolio with 36 issued patents and 32 patent filings covering its products in the major pharmaceutical markets. The Company believes its strong IP position provides not only freedom to operate but exclusivity in the key areas of its business. The first in class anti-bacterial compounds, NuBiotics, are protected by 4 issued US patents and 2 issued European patents. The Company believes these patents will provide market exclusivity for NuBiotics and related compounds until at least 2018 in the United States. The Company anticipates building on this portfolio as the drugs move forward into clinical trials to cover formulations and additional routes of delivery, thus expanding the length of patent protection.
The nRNA technology platform is protected by 8 issued patents containing both broad and gene specific claims providing freedom to operate in a complex intellectual property environment in key geographic and disease areas. In particular, Lakewood-Amedex recently received a Notice of Allowance for a broad claims antisense RNA patent in China that will provide a dominate position for combination RNA therapeutics and a leadership position in the growing Chinese pharmaceutical market. In addition, the Company continues to aggressively pursue additional filings as its scientists have improved the technology and now has an additional 27 patent applications covering improved chemistry and gene specific treatments. The Company is seeking licensing and development partners for nRNA therapeutics outside it core infectious disease area.
The Company’s hemolytic uremic syndrome program was acquired through a licensing agreement with Tuft’s University and is covered by three issued US Patents.